Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 2Active not recruiting 2Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Melanoma 5Breast Neoplasms 3Pancreatic Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Urogenital Neoplasms 1Thyroid Neoplasms 1Ovarian Cancer Metastatic 1Neoplasms 1Multiple Myeloma 1Metastatic HPV-16 Positive Squamous Cell Anal Cancer 1Metastatic Bladder Urothelial Carcinoma 1Liver Neoplasms 1Leukemia, Myeloid, Acute 1Head and Neck Neoplasms 1Fallopian Tube Neoplasms 1Duodenal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Adenocarcinoma of Lung 1

Interventions

Carboplatin 5niraparib 2Taxes 2Paclitaxel 2Gemcitabine 2Cyclophosphamide 2Bevacizumab 2talazoparib 1sargramostim 1palbociclib 1oregovomab 1olaparib 1epacadostat 1dostarlimab 1birinapant 1atezolizumab 1aldesleukin 1Specimen Handling 1Sirolimus 1Selenium 1Polymerase Chain Reaction 1N-(5-(2,3-dihydrobenzofuryl)sulfonyl)-N'-(3,4-dichlorophenyl)urea 1Metformin 1Magnetic Resonance Spectroscopy 1Letrozole 1Injections 1Hyperthermic Intraperitoneal Chemotherapy 1Gene Expression Profiling 1Fulvestrant 1Colony-Stimulating Factors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Fallopian Tube Neoplasms × aldesleukin × Clear all
NCT02470559 2016-02-17

Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent

Barbara Ann Karmanos Cancer Institute

Phase 1 Withdrawn
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡